EML-4-ALK Fusion

N/A

Report date: 2023/01/28 19:06:01

Base Information

Drug NameEML-4-ALK Fusion
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnaplastic lymphoma kinase inhibitors
TargetsAnaplastic lymphoma kinase
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusClinical
Highest Status in ChinaClinical
Originator CompaniesChinese Academy Of Medical Sciences
China Registration ClassN/A

Develop Information

Active CompaniesChinese Academy Of Medical Sciences
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A